<DOC>
	<DOCNO>NCT00762294</DOCNO>
	<brief_summary>Aromatase Inhibitors ( AI ) effective secondary prevention breast cancer may soon replace tamoxifen first-line therapy treatment hormone-sensitive breast cancer . However , medication produce mark reduction serum estrogen level , likely result increase rate bone loss risk develop osteoporosis fracture postmenopausal woman treat agent . Indeed , substantial bone loss report several large clinical trial AIs . Osteoporosis drug available could prevent loss , frequent side effect expensive . Thus , treat woman receive AIs might appropriate cost-effective approach . A good approach might select woman high risk bone loss treat antiresorptive agent . The propose pilot study evaluate woman receive anastrozole letrozole therapy , receive adequate amount calcium vitamin D baseline normal moderately low bone mass order determine early change bone turnover marker correlate bone loss one year . If data pilot protocol support hypothesis , would propose large trial confirm . The ultimate aim predict woman high risk bone loss therefore treat earlier bone-sparing agent , low risk could monitor conservative therapy .</brief_summary>
	<brief_title>Anastrozole Letrozole</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Postmenopausal woman diagnosis breast cancer start Arimidex Femara yet , start . History metastasis History chronic kidney Liver GI disease Disorders affect calcium metabolism</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>arimidex</keyword>
	<keyword>femara</keyword>
	<keyword>bone health</keyword>
</DOC>